Global Fibrodysplasia Ossificans Progressiva Treatment Market, By Drugs Class (Corticosteroids, NSAIDs, Bisphosphonates and Others), Drugs (Rituximab, Ascorbic Acid, Acetic Acid, and Others), Treatment (Medication, Occupational Therapy, and Surgery), Route of Administration (Oral, Topical and Parenteral), End-User (Hospitals, Research Institutes, Specialty Clinics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2030.
Fibrodysplasia Ossificans Progressiva Treatment Market Analysis and Size
Fibrodysplasia ossificans progressiva (FOP) is a rare hereditary disorder. The market is expected to expand rapidly in the few years. Introduction of novel therapies and rise in cases of fibrodysplasia ossificans progressiva are likely to be major drivers of the market. Increase in demand for the treatment of this disease and increase in awareness associated with FOP are also projected to drive the market during the forecast period.
Data Bridge Market Research analyses a growth rate in the fibrodysplasia ossificans progressiva treatment market in the forecast period 2023-2030. The expected CAGR of fibrodysplasia ossificans progressiva treatment market tend to be around 4% in the mentioned forecast period. The market was valued at USD 500 million in 2022 and it would grow upto USD 684.28 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Fibrodysplasia Ossificans Progressiva Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs Class (Corticosteroids, NSAIDs, Bisphosphonates and Others), Drugs (Rituximab, Ascorbic Acid Acetic Acid, and Others), Treatment (Medication, Occupational Therapy, and Surgery), Route of Administration (Oral, Topical and Parenteral),End-User (Hospitals, Research Institutes, Specialty Clinics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Novartis AG (Switzerland), Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH. (Germany), Merck & Co Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceuticals Industries Ltd. (Israel), AstraZeneca (U.K.), Lilly (U.S.), Zydus Group (India), Fresenius Kabi AG (Germany), Accord Healthcare, Inc. (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Regeneron Pharmaceuticals Inc (U.S.), Blueprint Medicines Corporation (U.S.), Ipsen Pharma (France), BIOCRYST PHARMACEUTICALS, INC. (U.S.), NATCO Pharma Limited (India), Thermo Fisher Scientific (U.S.), bioMérieux S.A. (France), Bayer AG (Germany), Bristol Myers Squibb Company (U.S.), and Abbott (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Fibrodysplasia ossificans progressiva (FOP) is a type of rare genetic disorder wherein the muscle tissue and connective tissue, such as the tendons and ligaments are substituted by bone, forming bone outside the skeleton that limits the movement of that specific part of the body. This can cause malformations such as shortened great toe with a malformed distal first metatarsal, abnormally short fingers and toes, inward turning of the great toe toward the other toes, or permanent fixation of the fifth finger in a bent position.
Fibrodysplasia Ossificans Progressiva Treatment Market Dynamics
Drivers
- Growing Incidence of Fibrodysplasia ossificans progressiva treatment
As per the Journal of Rare Disease Research and Treatment, in 2016, the incidence of FOP ranged considerably from around 0.65 per million in North America, 0.47 per million in Western Europe, and 0.27 per million in Latin America to 0.05 per million in Africa and nearly 0.04 per million in the Asia Pacific. Therefore, it acts as a major driver in the market growth.
- Increase in the number of R&D activities
The market's growth is fuelled by the increase in the number of R&D activities. This will provide much beneficial opportunities for the market. For instance, in January 2020, Regeneron Pharmaceuticals, Inc., which is an American pharmaceutical company, showcased the results from a Phase 2, double-blind placebo-controlled trial, LUMINA-1, the trial was originated to assess garetosmab for the treatment of fibrodysplasia ossificans progressiva.
Opportunities
- Increased Partnerships and Collaborations
There have been increased partnerships and collaborations between market players that lead to the growth of the market. For instance, In October 2019, Clementia Pharmaceuticals, a subsidiary of Ipsen, and Blueprint Medicines Corporation came into an exclusive license agreement to commercialize and develop BLU-782, which is a highly selective investigational ALK2 inhibitor, that is indicated for the treatment of fibrodysplasia ossificans progressiva (FOP).
Restraints/Challenges
- Lack of Awareness
The sales of potential products are not succeeding much due to the lack of awareness of the syndrome. Though effective treatments are available, but poor inadequate communication between clinicians and patients, treatment adherence impedes market growth.
- High Cost
The enormous expenditure associated with the treatment processes hinders market growth. Various market players make huge investments in installing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.
This fibrodysplasia ossificans progressiva treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the fibrodysplasia ossificans progressiva treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Fibrodysplasia Ossificans Progressiva Treatment Market Scope
The fibrodysplasia ossificans progressiva treatment market is segmented on the basis of drug class, drug, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Corticosteroids
- NSAIDs
- Bisphosphonates
- Others
Drugs
- Rituximab
- Ascorbic Acid
- Acetic Acid
- Others
Treatment
- Medication
- Occupational Therapy
- Surgery
Route of Administration
- Oral
- Topical
- Parenteral
End-User
- Hospitals
- Research Institutes
- Specialty Clinics
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Fibrodysplasia Ossificans Progressiva Treatment Market Regional Analysis/Insights
The fibrodysplasia ossificans progressiva treatment market is analyzed and market size insights and trends are provided by drug class, drug treatment, distribution channel, route of administration, and end-user as referenced above.
The major countries covered in the fibrodysplasia ossificans progressiva treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market because of high per capita income, favorable healthcare infrastructure, and high rate of adoption of advanced surgeries in the region.
Asia-Pacific is considered to have the most lucrative period due to the rise in cases of connective tissue disorders.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Fibrodysplasia Ossificans Progressiva Treatment Market Share Analysis
The fibrodysplasia ossificans progressiva treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to fibrodysplasia ossificans progressiva treatment market
Key players operating in the fibrodysplasia ossificans progressiva treatment market include:
- Pfizer Inc. (U.S.)
- Abbvie Inc. (U.S.)
- Novartis AG (Switzerland)
- Amgen Inc. (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Merck & Co Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceuticals Industries Ltd. (Israel)
- AstraZeneca (U.K.)
- Lilly (U.S.)
- Zydus Group (India)
- Fresenius Kabi AG (Germany)
- Accord Healthcare, Inc. (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Regeneron Pharmaceuticals Inc (U.S.)
- Blueprint Medicines Corporation (U.S.)
- Ipsen Pharma (France)
- BIOCRYST PHARMACEUTICALS, INC. (U.S.)
- NATCO Pharma Limited (India)
- Thermo Fisher Scientific (U.S.)
- bioMérieux S.A. (France)
- Bayer AG (Germany)
- Bristol Myers Squibb Company (U.S.)
- Abbott (U.S.)
SKU-